The shares of pharma major, Cipla decline as much as 0.64% in the intra day today after a surprise inspection by US health regulator. At 2.46pm, The stock were trading down by ₹1.60 at ₹651.60 (0.24%) .
The company came into spotlight soon after US Food and Drug Administration (USFDA) sent three auditors to inspect the plant today.
The Goa facility is among the largest plant catering 20-25% revenues from US markets. The plant has a key role in getting ANDA (Written request for New Drug) approved by USFDA. The Earlier this week, the stock gained 2% as USFDA approved anti-nausea drug of the company.
There is no response by the company to media queries by Economic Times regarding the audit.